Jorge A Carrasquillo1,2, Clara C Chen1, Susan Price3, Millie Whatley1, Nilo A Avila4, Stefania Pittaluga5, Elaine S Jaffe5, V Koneti Rao3. 1. From the Nuclear Medicine Division, Department of Radiology & Imaging Science, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD. 2. Currently at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY. 3. Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases. 4. Department of Radiology &Imaging Sciences, Warren Grant Magnuson Clinical Center, National Institutes of Health. 5. Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD.
Abstract
INTRODUCTION: Autoimmune lymphoproliferative syndrome (ALPS) is a rare immune dysregulatory condition, usually presenting in childhood with massive lymphadenopathy, splenomegaly, and an increased incidence of lymphoma. Methods to differentiate between benign ALPS adenopathy and lymphoma are needed. To this end, we evaluated the usefulness of FDG PET. METHODS: We prospectively evaluated 76 ALPS/ALPS-like patients including FS-7-associated surface antigen (FAS) germline mutation with (n = 4) and without lymphoma (n = 50), FAS-somatic (n = 6), ALPS-unknown (n = 6), and others (n = 10) who underwent FDG PET. Uptakes in 14 nodal sites, liver, and spleen were determined. RESULTS: In 76 ALPS patients, FDG PET showed uptake in multiple nodal sites in all but 1 patient. The highest SUVmax values in FAS mutation without lymphoma, FAS mutation with lymphoma, FAS somatic, ALPS-unknown, and other genetic mutations were a median (range) 9.2 (4.3-25), 16.2 (10.7-37.2), 7.6 (4.6-18.1), 11.5 (4.8-17.2), and 5.5 (0-15.3), respectively. Differences between uptake in the FAS group with and without lymphoma were statistically significant, but overlapped, making discrimination between individuals with/without lymphoma impossible. The spleen:liver uptake ratio was greater than 1 in 82% of patients. CONCLUSIONS: While statistically significant differences were observed in FAS mutation ALPS with and without lymphoma, the significant overlap in FDG uptake and visual appearance in many patients prevents discrimination between patients with and without lymphoma. Similar patterns of FDG biodistribution were noted between the various ALPS subgroups.
INTRODUCTION:Autoimmune lymphoproliferative syndrome (ALPS) is a rare immune dysregulatory condition, usually presenting in childhood with massive lymphadenopathy, splenomegaly, and an increased incidence of lymphoma. Methods to differentiate between benign ALPS adenopathy and lymphoma are needed. To this end, we evaluated the usefulness of FDG PET. METHODS: We prospectively evaluated 76 ALPS/ALPS-like patients including FS-7-associated surface antigen (FAS) germline mutation with (n = 4) and without lymphoma (n = 50), FAS-somatic (n = 6), ALPS-unknown (n = 6), and others (n = 10) who underwent FDG PET. Uptakes in 14 nodal sites, liver, and spleen were determined. RESULTS: In 76 ALPSpatients, FDG PET showed uptake in multiple nodal sites in all but 1 patient. The highest SUVmax values in FAS mutation without lymphoma, FAS mutation with lymphoma, FAS somatic, ALPS-unknown, and other genetic mutations were a median (range) 9.2 (4.3-25), 16.2 (10.7-37.2), 7.6 (4.6-18.1), 11.5 (4.8-17.2), and 5.5 (0-15.3), respectively. Differences between uptake in the FAS group with and without lymphoma were statistically significant, but overlapped, making discrimination between individuals with/without lymphoma impossible. The spleen:liver uptake ratio was greater than 1 in 82% of patients. CONCLUSIONS: While statistically significant differences were observed in FAS mutation ALPS with and without lymphoma, the significant overlap in FDG uptake and visual appearance in many patients prevents discrimination between patients with and without lymphoma. Similar patterns of FDG biodistribution were noted between the various ALPS subgroups.
Authors: Joao B Oliveira; Jack J Bleesing; Umberto Dianzani; Thomas A Fleisher; Elaine S Jaffe; Michael J Lenardo; Frederic Rieux-Laucat; Richard M Siegel; Helen C Su; David T Teachey; V Koneti Rao Journal: Blood Date: 2010-06-10 Impact factor: 22.113
Authors: Susan Price; Pamela A Shaw; Amy Seitz; Gyan Joshi; Joie Davis; Julie E Niemela; Katie Perkins; Ronald L Hornung; Les Folio; Philip S Rosenberg; Jennifer M Puck; Amy P Hsu; Bernice Lo; Stefania Pittaluga; Elaine S Jaffe; Thomas A Fleisher; V Koneti Rao; Michael J Lenardo Journal: Blood Date: 2014-01-07 Impact factor: 22.113
Authors: Christian Furth; Robert M Meseck; Ingo G Steffen; Stefan Schoenberger; Timm Denecke; Günter Henze; Hubertus Hautzel; Frank Hofheinz; Oliver Großer; Patrick Hundsdoerfer; Holger Amthauer; Juri Ruf Journal: Pediatr Blood Cancer Date: 2011-12-20 Impact factor: 3.167
Authors: N A Avila; A J Dwyer; J K Dale; U A Lopatin; M C Sneller; E S Jaffe; J M Puck; S E Straus Journal: Radiology Date: 1999-07 Impact factor: 11.105
Authors: Katherine R Calvo; Susan Price; Raul C Braylan; Joao Bosco Oliveira; Michael Lenardo; Thomas A Fleisher; V Koneti Rao Journal: Blood Date: 2015-02-17 Impact factor: 22.113
Authors: Douglas Brust; Michael Polis; Richard Davey; Barbara Hahn; Stephen Bacharach; Millie Whatley; Anthony S Fauci; Jorge A Carrasquillo Journal: AIDS Date: 2006-04-24 Impact factor: 4.177
Authors: Miroslawa Nowak; Jorge A Carrasquillo; Cheryl H Yarboro; Steven L Bacharach; Millie Whatley; Xavier Valencia; Kazuki Takada; Douglas G Brust; Gabor G Illei Journal: Arthritis Rheum Date: 2004-04
Authors: Dimitrios Karantanis; Jolanta M Durski; Val J Lowe; Mark A Nathan; Brian P Mullan; Evangelos Georgiou; Patrick B Johnston; Gregory A Wiseman Journal: Eur J Radiol Date: 2009-08-27 Impact factor: 3.528
Authors: Natascha Döbert; Christian Menzel; Uwe Berner; Nadja Hamscho; Nicola Wördehoff; Paris Mitrou; Frank Grünwald Journal: Cancer Biother Radiopharm Date: 2003-08 Impact factor: 3.099